Notícias e Atividades da Fortress Biotech

Fortress Biotech é uma empresa listada sob o símbolo FBIO (US).

Fortress Biotech possui 4 subsidiárias incluindo Avenue Therapeutics, Checkpoint Therapeutics e Journey Medical Corp.

Eles estão dentro:

• Biotecnologia80%
• Farmacêutica20%

Veja o organograma con seus 54 executivos principais

Biografias mais buscadas da Fortress Biotech

• Lindsay Rosenwald, Chairman, President, and Chief Executive Officer
• Jay Lobell, Director
• Kevin Lorenz, Director

Criar um alerta
para seguir os movimentos de executivos da Fortress Biotech.

Fortress Biotech possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Fortress Biotech

• Mustang Bio Announces Closing of $8 Million Public Offering
• Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
• Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
• Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
• Mustang Bio Announces Reverse Stock Split
• Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
• Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
• Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
• Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
• View more press releases Close

Redes sociais sobre Fortress Biotech

• Fortress Biotech na Wikipedia, Google News e Yahoo Finance
• Fortress Biotech na LinkedIn, Twitter e YouTube